

## Preplanned Studies

## Periconceptional Folic Acid Only Versus Multiple Micronutrients Containing Folic Acid and Association with Gestational Diabetes Mellitus — Beijing Municipality, China, 2017–2021

Shuangbo Xia<sup>1,2</sup>; Yushan Du<sup>1,2</sup>; Ziyang Ren<sup>1,2</sup>; Jinjuan Zhang<sup>1,2</sup>; Suhong Gao<sup>3</sup>; Jiamei Wang<sup>4</sup>; Zhiwen Li<sup>1,2</sup>; Xiaohong Liu<sup>4,#</sup>; Jufen Liu<sup>1,2,#</sup>

### Summary

#### What is already known about this topic?

Inconsistent results have been reported on the association between periconceptional folic acid only (FAO) or multiple micronutrients containing folic acid (MMFA) supplementation and the risk of gestational diabetes mellitus (GDM) in previous research.

#### What is added by this report?

In a prospective cohort study conducted among pregnant women in Haidian District, Beijing Municipality, it was observed that those who took MMFA demonstrated a higher likelihood of developing GDM in comparison to those who consumed FAO periconceptionally. Interestingly, the increased risk for GDM in pregnant women supplemented with MMFA compared to FAO was primarily due to changes in fasting plasma glucose.

#### What are the implications for public health practice?

It is highly recommended that women prioritize the use of FAO in order to yield potential benefits in the prevention of GDM.

Gestational diabetes mellitus (GDM) is defined as diabetes diagnosed in the second or third trimester of pregnancy that was not clearly overt diabetes prior to gestation, posing a serious risk to maternal and infant health (1). The prevalence of GDM in China has been increasing, with a recent meta-analysis revealing that the prevalence of GDM in China is 14.8% (2). Folic acid (FA) supplementation is widely promoted among pregnant women in China to reduce the risk of fetal neural tube defects. However, concerns have arisen about the potential effects of FA supplementation on maternal health. Recent studies investigating the association between FA supplementation and GDM have yielded inconclusive results, particularly in regards to maternal supplementation with FA only (FAO) or

with multiple micronutrients containing FA (MMFA) (3). This study analyzed data from a prospective cohort of pregnant women at the Haidian Maternal and Child Health Hospital in Beijing, China, during the period from 2017 to 2021, where the prevalence of GDM was 18.8%. The results revealed that women taking MMFA were more likely to develop GDM than women taking FAO.

This ongoing prospective cohort study focuses on pregnant women and has been previously described in detail (4). From October 2017 to October 2021, 4,239 pregnant women at or before 20 weeks of gestation were recruited at the Haidian Maternal and Child Health Hospital in Beijing, China. A structured questionnaire, which included demographic characteristics and detailed FA supplementation information, was administered during recruitment. Information on periconceptional FA supplementation among pregnant women included whether they took supplements (no or yes), type of supplements (FAO or MMFA), timing (before or after conception), and frequency (>24 or ≤24 capsules/month). Frequency of FA supplementation was divided into two groups based on 80% of the recommended standard (30 capsules/month).

After recruitment, the pregnant women underwent the oral glucose tolerance test (OGTT) for blood glucose at 24–28 weeks of pregnancy. GDM diagnosis followed the International Association of Diabetes and Pregnancy Study Group criteria, which required that a pregnant woman met one or more of the following criteria: fasting plasma glucose (FPG) ≥5.1 mmol/L, 1-hour plasma glucose (1 h PG) ≥10.0 mmol/L during OGTT, or 2-hour plasma glucose (2 h PG) ≥8.5 mmol/L during OGTT (1). A total of 818 women were excluded due to unclear information on FA intake, missing OGTT results at 24–28 weeks of pregnancy, and a history of pre-pregnancy diabetes or first-degree family history of diabetes. Consequently, the final analysis included data from 3,421 women.

This study was approved by the Biomedical Institutional Review Board of Peking University (IRB00001052-17028), and written consent was obtained from all participants.

In this study, binary logistic regression was employed to analyze the association between FA supplementation and GDM while adjusting for potential confounding variables. These variables, such as maternal age and pre-pregnancy body mass index (BMI), were chosen based on previously relevant studies (5). Additionally, certain food consumption characteristics were included since food can serve as a source of dietary folate. Outcome variables like FPG GDM, 1 h PG-GDM, and 2 h PG-GDM were defined based on distinct testing time points, which were utilized to further explore the association between FA supplementation and different GDM subtypes. The logistic analysis results are presented as odds ratios (ORs) and 95% confidence intervals (95% CIs). All analyses were conducted using R software (version 4.0.5; R Development Core Team, Vienna, Austria). A two-tailed  $P \leq 0.05$  was considered statistically

significant.

A total of 3,421 women were included in the final analysis, with ages ranging from 20 to 49 years old (mean=30.2, SD=3.7). Of these participants, 17.5% were classified as above normal weight before conception, with a pre-pregnancy BMI  $\geq 24$  kg/m<sup>2</sup>. Among the sample, 643 women (18.8%) were diagnosed with GDM. A higher prevalence of GDM was observed among older, more obese, multiparous, less educated women, and those exposed to smoking (all  $P < 0.05$ ). Additionally, GDM prevalence was higher among women who reported higher consumption of eggs and milk ( $P < 0.05$ ). However, no significant differences were observed in terms of occupation, ethnicity, education, or the frequency of meat, vegetable, fruit, and soybean consumption (all  $P > 0.05$ ) (Table 1).

Table 2 demonstrates that only 3.2% (109/3,421) of participants did not take FA periconceptionally, while 26.2% (880/3,421) took FAO, and the majority, 70.6% (2,432/3,421), took MMFA. Women who took MMFA were more likely to develop GDM compared

TABLE 1. Characteristics of pregnant women between groups of GDM and non-GDM in Beijing, China, 2017–2021, *n* (%).

Variable	Total*	Non-GDM*	GDM*	<i>P</i> value <sup>†</sup>
Total	3,421 (100.0)	2,778 (81.2)	643 (18.8)	
Age (years)				<0.001
<30	1,675 (49.0)	1,411 (84.2)	264 (15.8)	
$\geq 30$	1,746 (51.0)	1,367 (78.3)	379 (21.7)	
Pre-pregnancy BMI (kg/m <sup>2</sup> )				<0.001
<24	2,654 (81.6)	2,219 (83.6)	435 (16.4)	
$\geq 24$	598 (18.4)	414 (69.2)	184 (30.8)	
Occupation				0.072
None	219 (6.5)	168 (76.7)	51 (23.3)	
Teacher/doctor/technician	1,109 (32.8)	927 (83.6)	182 (16.4)	
Business/service	791 (23.4)	642 (81.2)	149 (18.8)	
Public official	698 (20.7)	554 (79.4)	144 (20.6)	
Others	562 (16.6)	458 (81.5)	104 (18.5)	
Education				0.031
Master or above	957 (27.7)	795 (83.9)	152 (16.1)	
College or university	2,247 (65.1)	1,790 (80.4)	436 (19.6)	
High school or below	250 (7.2)	191 (78.3)	53 (21.7)	
Ethnicity				0.875
Han	3,208 (93.8)	2,629 (81.1)	613 (18.9)	
Others	211 (6.2)	175 (81.8)	39 (18.2)	
Smoking				0.003
No	2,574 (76.0)	2,120 (82.4)	454 (17.6)	
Yes <sup>§</sup>	813 (24.0)	631 (77.3)	182 (22.7)	
Parity				0.014
Nulliparous	2,464 (80.6)	2,020 (82.0)	444 (18.0)	
Multiparous	593 (19.4)	460 (77.6)	134 (22.4)	

TABLE 1. (Continued)

Variable	Total*	Non-GDM*	GDM*	P value <sup>†</sup>
Food consumption				
Meat (times/week)				0.198
≤3	1,965 (59.8)	1,610 (81.9)	365 (18.1)	
4–6	727 (22.1)	588 (80.9)	139 (19.1)	
>6	595 (18.1)	468 (78.7)	127 (21.3)	
Egg (times/week)				0.026
≤3	1,094 (32.2)	913 (83.5)	181 (16.5)	
4–6	1,116 (33.8)	903 (80.9)	213 (19.1)	
>6	1,087 (33.0)	858 (78.9)	229 (21.1)	
Milk (times/week)				0.015
≤3	1,253 (38.0)	1,048 (83.6)	205 (16.4)	
4–6	995 (30.2)	788 (79.2)	207 (20.8)	
>6	1,046 (31.8)	837 (80.0)	209 (20.0)	
Vegetable (times/week)				0.138
≤3	326 (9.9)	274 (84.0)	52 (16.0)	
4–6	809 (24.6)	668 (82.6)	141 (17.4)	
>6	2,159 (65.5)	1,733 (80.3)	426 (19.7)	
Fruit (times/week)				0.554
≤3	173 (5.2)	146 (84.4)	27 (15.6)	
4–6	637 (19.3)	518 (81.3)	119 (18.7)	
>6	2,492 (75.5)	2,020 (81.1)	472 (18.9)	
Soybean (times/week)				0.652
≤3	1,898 (57.9)	1,553 (81.8)	345 (18.2)	
4–6	865 (26.4)	698 (80.7)	167 (19.3)	
>6	514 (15.7)	413 (80.4)	101 (19.6)	

Abbreviation: GDM=gestational diabetes mellitus; BMI=body mass index.

\* The total value differs from the sum of subgroups due to the exclusion of cases with missing data.

<sup>†</sup> Differences in prevalence of GDM by subcategory were examined with the Chi-square test.

<sup>§</sup> Smoking included exposure to passive smoking.

to those on FAO (adjusted  $OR=1.34$ , 95%  $CI$ : 1.05–1.72). No significant difference in GDM prevalence was observed between women taking FAO and those without FA supplementation (adjusted  $OR=0.76$ , 95%  $CI$ : 0.37–1.55). Furthermore, no associations were detected between the initial time or frequency of FA supplementation and GDM, regardless of stratification by type (all  $P>0.05$ ).

When analyzing the association between FA supplementation and GDM subtypes, the results showed that the increased risk for GDM in pregnant women supplemented with MMFA compared to FAO was primarily due to changes in FPG (adjusted  $OR=1.40$ , 95%  $CI$ : 1.02–1.92). FA supplementation type was not associated with 1 h PG-GDM and 2 h PG-GDM (all  $P>0.05$ ). (Figure 1).

## DISCUSSION

We investigated the association between maternal

FA supplementation and GDM using a prospective cohort in Haidian District, Beijing. Our results revealed that the GDM prevalence in Beijing was 18.8%, which was slightly higher than the reported prevalence in Beijing in 2017 (17.2%) (5), and surpassing that in China (14.8%) (2). This suggests that GDM prevalence in Beijing is relatively high and continues to increase. Furthermore, only 3.2% of participants did not take FA periconceptionally, and more women opted for MMFA than FAO, which aligns with another survey conducted in Beijing (6). These findings underline the importance of exploring the effects of FAO/MMFA supplementation on GDM.

Our study found that pregnant women taking MMFA had a higher likelihood of developing GDM compared to those taking FAO. We observed no significant difference in GDM risk between women who took FAO and those without supplementation, suggesting that appropriate FA supplementation does not increase GDM risk. Several possible explanations for this association exist.

TABLE 2. Association between folic acid supplementation and GDM in pregnant women in Beijing, China, 2017–2021.

FA supplementation	Total	GDM	Crude OR (95% CI)*	Adjusted OR (95% CI)†
Total	3,421	643 (18.8)	–	–
FA supplementation				
No	109	15 (13.8)	Reference	Reference
Yes	3,312	628 (19.0)	1.47 (0.84–2.55)	1.52 (0.80–2.87)
Type				
FAO	880	145 (16.5)	Reference	Reference
MMFA	2,432	483 (19.9)	1.26 (1.02–1.54)	1.34 (1.05–1.72)
Nonusers	109	15 (13.8)	0.81 (0.46–1.44)	0.76 (0.37–1.55)
Initial time				
Nonusers	109	15 (13.8)	Reference	Reference
Before conception	1,689	317 (18.8)	1.45 (0.83–2.53)	1.60 (0.80–3.22)
After conception	1,623	311 (19.2)	1.49 (0.85–2.60)	1.64 (0.82–3.30)
Supplement frequency				
Nonusers	109	15 (13.8)	Reference	Reference
≤24 capsules per month	675	141 (20.9)	1.66 (0.93–2.94)	1.82 (0.89–3.72)
>24 capsules per month	2,557	472 (18.5)	1.42 (0.82–2.47)	1.55 (0.77–3.10)
Stratified by types				
Initial time				
FAO				
Nonusers	109	15 (13.8)	Reference	Reference
Before conception	465	69 (14.8)	1.09 (0.60–1.99)	1.36 (0.72–2.59)
After conception	415	76 (18.3)	1.41 (0.77–2.56)	1.60 (0.85–3.00)
MMFA				
Nonusers	109	15 (13.8)	Reference	Reference
Before conception	1,224	248 (20.3)	1.59 (0.91–2.80)	1.78 (0.88–3.60)
After conception	1,208	235 (19.5)	1.51 (0.86–2.66)	1.68 (0.83–3.39)
Supplement frequency				
FAO				
Nonusers	109	15 (13.8)	Reference	Reference
≤24 capsules per month	190	37 (19.5)	1.52 (0.79–2.91)	1.87 (0.81–4.31)
>24 capsules per month	658	105 (16.0)	1.19 (0.66–2.13)	1.48 (0.68–3.21)
MMFA				
Nonusers	109	15 (13.8)	Reference	Reference
≤24 capsules per month	485	104 (21.4)	1.71 (0.95–3.08)	1.88 (0.91–3.90)
>24 capsules per month	1,899	367 (19.3)	1.50 (0.86–2.62)	1.65 (0.82–3.32)

Abbreviation: FA=Folic acid; GDM=gestational diabetes mellitus; OR=odds ratio; CI=confidence interval; FAO=folic acid only; MMFA=multiple micronutrients containing folic acid.

\* crude OR: logistic regression. No confounders were adjusted.

† adjusted OR: logistic regression. Adjusted for maternal age, pre-pregnancy BMI, occupation, education, parity, smoking, and consumption of eggs, milk, vegetables, and fruits.

“–” means data not available.

First, a dose-response relationship may exist between FA and GDM. The main brand of MMFA contains twice the amount of FA (0.8 mg/tablet) as a simple FA

tablet (0.4 mg/tablet) (6). Excessive FA can lead to increased circulating unmetabolized folate, which in turn elevates homocysteine levels. This elevation has




FIGURE 1. Association between folic acid supplementation and various subtypes of gestational diabetes mellitus among pregnant women in Beijing, China, 2017–2021.

Abbreviation: GDM=gestational diabetes mellitus; OR=odds ratio; FAO=folic acid only; MMFA=multiple micronutrients containing folic acid; FPG-GDM=GDM diagnosed by fasting plasma glucose; 1 h PG-GDM=GDM diagnosed by 1-hour plasma glucose during OGTT; 2 h PG-GDM=GDM diagnosed by 2-hour plasma glucose during OGTT.

\* OR: logistic regression. Adjusted for maternal age, pre-pregnancy BMI, occupation, education, parity, smoking, and consumption of eggs, milk, vegetables, and fruits.

been associated with increased oxidative stress and impaired pancreatic  $\beta$ -cell function (7). As we did not investigate FA supplementation quantity and dosage, further research should examine the dose-response relationship between FA and GDM.

Second, other nutrients play important roles in numerous cellular and physiological processes. Excessive levels of certain micronutrients in MMFA, such as iron, have been associated with GDM (8). WHO guidelines do not recommend promoting MMFA in pregnant women due to insufficient evidence of its benefits for neonatal survival, growth, or cognitive function compared to FAO. Additionally, MMFA supplementation may pose an increased economic burden for pregnant women (9). Although we did not investigate the specific nutrient contents and doses of MMFA, our results support prioritizing FAO supplementation for GDM prevention. Our study supports the WHO's recommendation by emphasizing the potential risks of MMFA for women's health.

Previous research examining the relationship between FA supplementation and GDM has yielded inconsistent findings; some studies have reported a protective effect, while others have found no association or even harmful outcomes (3). These discrepancies are generally attributed to variations in study populations with regard to GDM prevalence, diagnostic criteria, as well as dietary and lifestyle differences. Notably, few investigations have distinguished between types of FA supplementation or

considered the influence of other vitamins and minerals. In our cohort, the majority of pregnant women opted for MMFA supplementation, and a significant difference in GDM risk was observed between those taking FAO and those using MMFA. To the best of our knowledge, this study is the first to illuminate the distinct effects of FAO and MMFA on GDM risk, laying the groundwork for future research exploring the relationship between FA supplementation and GDM.

We further compared the effects of FA supplementation on various subtypes of GDM. The findings indicated that MMFA supplementation primarily affected FPG levels, increasing the risk of developing GDM. Previous studies have demonstrated a relationship between vitamin B12 levels and FPG; however, no significant associations were observed between vitamin B12 and either 1 h PG or 2 h PG (10). This may suggest that FPG serves as a more sensitive indicator for GDM diagnosis and predicting risk factors.

Our study exhibited multiple strengths. First, as a prospective cohort study, it excluded women with a history of diabetes mellitus, allowing for the prospective determination that FA supplementation significantly contributed to the heightened risk for GDM. Second, by controlling the consumption frequency of fruits, vegetables, and other foods, we effectively eliminated the influence of dietary FA intake on the results. Lastly, through stratification of the FA supplementation types, we were able to investigate the



associations between specific characteristics of FA supplementation and GDM.

This study, however, is subject to several limitations. The population was drawn from Beijing, which has a high standard of living and nutritional status, potentially limiting the generalizability of the results. The older maternal age and prevalence of GDM, as well as potential genetic and environmental factors, may also affect the findings. Additionally, we were unable to obtain and compare the specific components of the MMFA, and our analysis did not investigate the duration or dose of FA supplementation, although we did incorporate frequency. Lastly, we did not examine the association between blood FA levels and GDM; further research is warranted in this area.

In conclusion, our study suggests that maternal periconceptional supplementation with MMFA may result in an increased risk for GDM when compared to FAO supplementation. Pregnant women ought to be cognizant of the potential issues related to over supplementation of certain micronutrients. As new population policies are implemented, the proportion of pregnant women of advanced age continues to rise. Concurrently, improved nutritional status among pregnant women has been observed, as evidenced by increased instances of overweight and excessive gestational weight gain during pregnancy. These factors may contribute to a heightened prevalence of GDM among expectant mothers. Our findings indicate that pregnant women should prioritize FAO supplementation as a preventive measure against GDM. Further research is warranted to inform clinical practice and aid women in reducing the risk of GDM and other associated metabolic diseases.

**Conflicts of interest:** No conflicts of interest.

**Acknowledgements:** The authors would like to thank all the participants in this study. The authors also thank the health care workers at Haidian Maternal and Child Health Hospital for their assistance with data collection.

**Funding:** The Fundamental Research Funds for the Central Universities (BMU2021YJ034); CNS-ZD Tizhi and Health Fund (CNS-ZD2020-115); National Natural Science Foundation of China (81673177).

doi: 10.46234/ccdcw2023.095

# Corresponding authors: Jufen Liu, liujufen@bjmu.edu.cn; Xiaohong Liu, 13522099566@163.com.

<sup>1</sup> Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China; <sup>2</sup> Institute of Reproductive and Child Health / National Health Commission Key Laboratory of Reproductive Health, Peking University, Beijing, China; <sup>3</sup> Department of Child Health, Beijing Haidian Maternal and Child Health Hospital, Beijing, China; <sup>4</sup> Department of Gynaecology and Obstetrics, Beijing Haidian Maternal and Child Health Hospital, Beijing, China.

Submitted: April 07, 2023; Accepted: May 06, 2023

## REFERENCES

- American Diabetes Association. 2. Classification and diagnosis of diabetes: *Standards of Medical Care in Diabetes—2020*. *Diabetes Care* 2020;43(S1):S14-31. <http://dx.doi.org/10.2337/dc20-S002>.
- Gao CH, Sun X, Lu L, Liu FW, Yuan J. Prevalence of gestational diabetes mellitus in mainland China: A systematic review and meta-analysis. *J Diabetes Investig* 2019;10(1):154 – 62. <http://dx.doi.org/10.1111/jdi.12854>.
- Xia SB, Zhang JJ, Chen X, Du YS, Liu JF. Association between folic acid supplementation and the risk for gestational diabetes mellitus: a meta-analysis. *Chin J Evid-Based Med* 2022;22(12):1445 – 52. <http://dx.doi.org/10.7507/1672-2531.202207061>. (In Chinese).
- Song QF, Wei J, Wang JM, Zhang L, Liu XH, Zhang YL, et al. Rate of correct use of folic acid supplementation among pregnant women - Beijing municipality, China, 2017-2019. *China CDC Wkly* 2021;3(37):783 – 7. <http://dx.doi.org/10.46234/ccdcw2021.194>.
- Jia XQ, Zhang L, Zhao J, Ren MY, Li ZW, Wang JM, et al. Associations between endocrine-disrupting heavy metals in maternal hair and gestational diabetes mellitus: A nested case-control study in China. *Environ Int* 2021;157:106770. <http://dx.doi.org/10.1016/j.envint.2021.106770>.
- Zhang J, Jin L, Wang D, Wang C, Tong MK, Yu JH, et al. Maternal periconceptional folic acid supplements use and fetus risk for limb defects. *Paediatr Perinat Epidemiol* 2021;35(6):645 – 53. <http://dx.doi.org/10.1111/ppe.12775>.
- Williamson JM, Arthurs AL, Smith MD, Roberts CT, Jankovic-Karasoulos T. High folate, perturbed one-carbon metabolism and gestational diabetes mellitus. *Nutrients* 2022;14(19):3930. <http://dx.doi.org/10.3390/nu14193930>.
- Kataria Y, Wu YX, De Hemmer Horskjær P, Mandrup-Poulsen T, Ellervik C. Iron status and gestational diabetes-a meta-analysis. *Nutrients* 2018;10(5):621. <http://dx.doi.org/10.3390/nu10050621>.
- WHO Guidelines Approved by the Guidelines Review Committee. WHO recommendations on antenatal care for a positive pregnancy experience. Geneva: World Health Organization. 2016. <https://www.who.int/publications/i/item/9789241549912>. [2023-4-10].
- Wang YG, Wang YY, Sun Y, Zhang NJ, Liang XS, Luo SH, et al. Serum folate mediates the associations of *MTHFR* rs1801133 polymorphism with blood glucose levels and gestational diabetes mellitus in Chinese Han pregnant women. *Br J Nutr* 2023;9:1 – 9. <http://dx.doi.org/10.1017/S0007114523000314>.